Grand Pharma
Grand Pharma is a privately held Hungarian pharmaceutical company headquartered in Nyíregyháza, founded in 2004, that operates as a drug retailer and wholesaler with 11–50 employees.
- Company typePrivate
- Founded2004
- HeadquartersNyíregyháza, Hungary
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Grand Pharma does
Per the firmographic record, Grand Pharma is a for-profit pharmaceutical company headquartered in Nyíregyháza, Hungary, that specializes in drug retailing and wholesaling. It was founded in 2004 and operates as a private entity with a headcount of 11–50 employees. The company maintains a web presence at grandpatika.hu; other firmographic details such as customer segments, pricing, and product mix are not disclosed in the available data.
The remaining aggregated data blocks describe a substantially different profile — a pharmaceutical operator with reported presence in China (CHN, Asia per source) that received regulatory approval to launch what is described as the world's first approved drug for Demodex Blepharitis, an eyelash/eyelid condition caused by Demodex mites. This profile is inconsistent with the firmographic data (small Hungarian pharmacy, 11–50 staff, drug retail/wholesale focus) and most likely reflects contamination from China Grand Pharmaceutical & Healthcare Holdings, a larger Hong Kong-listed pharmaceutical group that shares the "Grand Pharma" name. No financial details (revenue, funding rounds, ownership structure) are disclosed in any source.
Given the data conflict, the substantive descriptive basis is the firmographic profile: a small, privately held Hungarian pharmaceutical retailer/wholesaler with a single headquarters in Nyíregyháza and limited public information on products, customers, channels, or pricing beyond its core trade description.
Grand Pharma firmographics
Firmographics- Name
- Grand Pharma
- Website
- https://grandpatika.hu
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Grand Pharma is a privately held Hungarian pharmaceutical company headquartered in Nyíregyháza, founded in 2004, that operates as a drug retailer and wholesaler with 11–50 employees.
- Ownership category
- akta.pro rank
Grand Pharma industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmacies and Drug Retailers (45611), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Retail-Drug Stores And Proprietary Stores (5912), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC)
- akta.pro secondary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
Keywords
Where Grand Pharma is headquartered
LocationHeadquarters
- HQ city
- Nyíregyháza
- HQ country
- Hungary
- HQ region
- Europe
Markets served
Grand Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel
Grand Pharma product offering
Product offeringCore offering
Grand Pharma is a pharmaceutical company that sells drugs through retail and wholesale distribution channels. The company has also developed and received regulatory approval for a Demodex Blepharitis eye drug, described as the world's first approved treatment for Demodex blepharitis, with launch authorized in China.
Differentiator
Problem solved
Functional benefit
Products and services
- Demodex Blepharitis Eye Drug
Companies that use Grand Pharma
Customer profileIdeal customer profiles1 record
Grand Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Grand Pharma partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights2 records
Grand Pharma competitors and assessment
Company assessmentBroad incumbents
- Allergan / AbbVie: Allergan (now part of AbbVie) operates a leading ophthalmology pharmaceutical portfolio including treatments for ocular surface conditions and is a broad incumbent comparable to Grand Pharma on specialty ophthalmology products.
- Bausch + Lomb (Bausch Health): Bausch + Lomb is a major global ophthalmology pharmaceutical and medical-device company with established presence across eye-care indications including ocular surface disease. It is a broad incumbent comparable to Grand Pharma on the ophthalmology pharmaceutical axis, though operating at vastly greater scale and breadth.
- Novartis (Ophthalmology division): Novartis operates a major ophthalmology pharmaceutical franchise globally, including products for ocular surface conditions. It is a broad incumbent comparable to Grand Pharma on the ophthalmology pharmaceutical category, particularly relevant given the Demodex Blepharitis eye-drug overlap with ocular surface disease.
Regional players
- Czech Drug Center (Czech Pharma): Czech Drug Center and similar CEE pharma wholesalers operate regional drug distribution networks comparable in business model to Grand Pharma, though focused on Czech/Slovak markets rather than Hungary.
Direct peers
- Hungaropharma: Hungaropharma is one of Hungary's largest pharmaceutical wholesalers, distributing medicines to pharmacies and hospitals nationwide. It is directly comparable to Grand Pharma as a Hungarian drug wholesaler, though it operates at substantially greater scale.
- PHOENIX Group: PHOENIX Group is a leading European pharmaceutical wholesale and retail pharmacy operator with significant presence in Hungary and CEE. It is directly comparable to Grand Pharma on drug wholesaling and pharmacy retail business model across European geographies.
- China Grand Pharmaceutical and Healthcare Holdings: China Grand Pharmaceutical is a Hong Kong-listed specialty pharmaceutical company that has launched Demodex-related ophthalmology products in China. It is a direct peer on both the ophthalmology specialty pharma product axis and the China commercialization axis referenced in Grand Pharma's source data.
Emerging players
- Santen Pharmaceutical: Santen is a Japan-headquartered specialty ophthalmology pharmaceutical company with a global footprint including Asia. It is comparable to Grand Pharma on the ophthalmology specialty pharma axis, particularly given the China-focused ophthalmology product in Grand Pharma's portfolio.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Grand Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Grand Pharma leadership team
Management profileNumber of profiles
Grand Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Grand Pharma M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Grand Pharma
What does Grand Pharma do?
Grand Pharma is a pharmaceutical company that sells drugs through retail and wholesale distribution channels. The company has also developed and received regulatory approval for a Demodex Blepharitis eye drug, described as the world's first approved treatment for Demodex blepharitis, with launch authorized in China.
When was Grand Pharma founded?
Grand Pharma was founded in 2004. It employs 11 to 50 people.
Where is Grand Pharma based?
Grand Pharma is headquartered in Nyíregyháza, Hungary, in the Europe region.
Who are Grand Pharma's main competitors?
Broad incumbents on record are Allergan / AbbVie, Bausch + Lomb (Bausch Health) and Novartis (Ophthalmology division). Czech Drug Center (Czech Pharma) is listed as a regional player. Direct peers are Hungaropharma, PHOENIX Group and China Grand Pharmaceutical and Healthcare Holdings. Santen Pharmaceutical is listed as an emerging player.
Does Grand Pharma have an API?
No public API is recorded for Grand Pharma.
What industry is Grand Pharma in?
Grand Pharma's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAFALAC, Specialty Pharmacies (Complex/High-Cost Therapies), with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 45611 and its SIC code is 5912.